These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Construction of a reference material panel for detecting Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175 [TBL] [Abstract][Full Text] [Related]
3. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients. Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients. Salvianti F; Massi D; De Giorgi V; Gori A; Pazzagli M; Pinzani P Cancer Biomark; 2019; 26(3):271-279. PubMed ID: 31524142 [TBL] [Abstract][Full Text] [Related]
5. Monitoring Melanoma Using Circulating Free DNA. Diefenbach RJ; Lee JH; Rizos H Am J Clin Dermatol; 2019 Feb; 20(1):1-12. PubMed ID: 30374893 [TBL] [Abstract][Full Text] [Related]
6. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients. Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850 [TBL] [Abstract][Full Text] [Related]
7. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy. Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333 [TBL] [Abstract][Full Text] [Related]
8. Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients. Emelyanova MA; Telysheva EN; Orlova KV; Ryabaya OO; Snigiryova GP; Abramov IS; Mikhailovich VM Cancer Genet; 2021 Jan; 250-251():25-35. PubMed ID: 33249369 [TBL] [Abstract][Full Text] [Related]
9. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing. Holm M; Andersson E; Osterlund E; Ovissi A; Soveri LM; Anttonen AK; Kytölä S; Aittomäki K; Osterlund P; Ristimäki A PLoS One; 2020; 15(11):e0239819. PubMed ID: 33237900 [TBL] [Abstract][Full Text] [Related]
10. Diversity of circulating tumor cells in peripheral blood: Detection of heterogeneous BRAF mutations in a patient with advanced melanoma by single-cell analysis. Kiniwa Y; Nakamura K; Mikoshiba A; Akiyama Y; Morimoto A; Okuyama R J Dermatol Sci; 2018 May; 90(2):211-213. PubMed ID: 29426605 [No Abstract] [Full Text] [Related]
11. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid. Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598 [TBL] [Abstract][Full Text] [Related]
12. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Momtaz P; Pentsova E; Abdel-Wahab O; Diamond E; Hyman D; Merghoub T; You D; Gasmi B; Viale A; Chapman PB Oncotarget; 2016 Dec; 7(51):85430-85436. PubMed ID: 27863426 [TBL] [Abstract][Full Text] [Related]
13. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer. Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762 [TBL] [Abstract][Full Text] [Related]
14. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379 [TBL] [Abstract][Full Text] [Related]
15. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316 [TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients. Marczynski GT; Laus AC; Dos Reis MB; Reis RM; Vazquez VL Sci Rep; 2020 Oct; 10(1):18682. PubMed ID: 33122747 [TBL] [Abstract][Full Text] [Related]
17. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791 [TBL] [Abstract][Full Text] [Related]
18. Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma. Polivka J; Gouda MA; Sharif M; Pesta M; Huang H; Treskova I; Woznica V; Windrichova J; Houfkova K; Kucera R; Fikrle T; Ricar J; Pivovarcikova K; Topolcan O; Janku F Cancer Med; 2024 Oct; 13(19):e70313. PubMed ID: 39387479 [TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma. Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723 [TBL] [Abstract][Full Text] [Related]
20. Detection of BRAFV600E Mutation in Melanoma Patients by Digital PCR of Circulating DNA. Burjanivova T; Malicherova B; Grendar M; Minarikova E; Dusenka R; Vanova B; Bobrovska M; Pecova T; Homola I; Lasabova Z; Plank L Genet Test Mol Biomarkers; 2019 Apr; 23(4):241-245. PubMed ID: 30676087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]